Zhilin Group obtained the Phase 1 clinical trial license for ALS-4, a small molecule drug used to treat Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus (MRSA)) infections, from the Public Health Agency of Canada

NoSuchKey

Guess you like

Origin blog.csdn.net/sinat_41698914/article/details/112994246